Press Releases Year None20222021202020192018 Feb 23, 2022 Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Feb 17, 2022 Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 Feb 10, 2022 Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference Jan 13, 2022 Vaxcyte Announces Pricing of $100 Million Public Offering Jan 12, 2022 Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Jan 06, 2022 Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 16 of 16
Year None20222021202020192018 Feb 23, 2022 Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Feb 17, 2022 Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 Feb 10, 2022 Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference Jan 13, 2022 Vaxcyte Announces Pricing of $100 Million Public Offering Jan 12, 2022 Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Jan 06, 2022 Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Displaying 11 - 16 of 16
